Abstract:OBJECTIVE:To study the relationship between surface markers of CD56 and CD19 and karyotypes and prognosis in multiple myeloma.METHODS:A total of 126 cases of newly diagnosed multiple myeloma in the first hospital of Peking university from 2011 to 2015 were enrolled in this study. Cytogenetic abnormalities and immunophenotypes were detected by using fluorescence in situ hybridization and flow cytometry respectively before chemotherapy. Bone marrow smear was used for detection of abnormal plasma cell infiltration. By combining with their basic data, the relationship between immunophenotypes, cytogenetics and prognosis of MM was analyzed.RESULTS:(1) The median of myeloma cells in the 126 patients was 0.24（0.01-0.97）; the median of myeloma cells in 116 patients who have immunophenotype datas was 0.25（0.01-0.97）； the median of myeloma cells in CD19 positive patients was 0.11（0.01-0.53）; the median of myeloma cells in CD19 negative patients was 0.26（0.01-0.97）. The median of myeloma cells in CD19 positive patients was much lower than that in CD19 negative patients（P=0.036）. (2)In 116 patients detected by the immunophenotype, the myeloma cells expressed CD19,CD20,CD56 and CD117. Compared with CD56 negative patients(45/116,38.79%),CD56 positive patients(71/116,61.21%) had a clearly favorable disease outcome（OS was 53.0 month vs 31.0 month,P=0.016; PFS was 37.5 months vs 18.4 months, P=0.036）. (3)CD19 positive patients was 16.38%（19/116）,CD19 negative patients was 83.62%（97/116）； CD19 positive MM and CD19 negative MM had no difference in OS and PFS. (4)CD117 positive rate in CD19 positive patients was 42.11%(8/19), the CD117 positive rate in CD19 negative patients was 18.57%(18/97), the CD19 expression positively correlated with CD117 expression. (5)FISH detection was done for 67 newly diagnosed MM patients, 8 patients showed normal karyotypes(11.94%), 59 patients had abnormal karyotypes(88.06%). The most common abnormal karyotypes were IgH rearragement which occurred in 47 patients(70.15%). Other abnormal karyotypes included 1q21+, del(13q14),del(13q14.3),del(17p13) . These abnormal karyotypes occurred in 37 patients（55.22%）,31 patients（46.27%）,33 patients（49.25%） and 13 patients（19.40%） respectively. In comparison with CD19 negative MM patients, the incidence rate of 1q21+ and del(13q14.3) was significantly lower in CD19 positive patients(1q21+:33.33% vs 61.54%,P=0.016; del(13q14.3): 33.33% vs 53.85%,P=0.043）.CONCLUSION:The prognosis of CD56 positive MM patients is better than that of CD56 negative MM patients, CD19 negative MM has more abnormal karyotypes and bone marrow infiltration,but they have no statistical prognostic differences.

[The Relationship between the Expressions of CD33 and CD13 and the Prognosis of Patients with Multiple Myeloma].

Expression of CD269 and CD317 in Multiple Myeloma and Its Clinical Significance

Expressions of CD117 and CD28 in Patients with Newly Diagnosed Multiple Myeloma and Their Clinical Significances

Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis

Correlation Between Expression of CXCL12, CXCR4, VEGF, MVD and Prognosis in Patients with Multiple Myeloma

The Expression Of Cd200 As A Prognostic Factor In Newly Diagnosed Multiple Myeloma

[Correlation Between Expression of CD200 and Regulatory T Cells in Multiple Myeloma and Its Significance in Prognostic Stratification].

Changes of Peripheral Blood Lymphocyte Subsets and Cytokines in Patients with Multiple Myeloma and Their Clinical Significance

CD27 Antigen Negative Expression Indicates Poor Prognosis in Newly Diagnosed Multiple Myeloma

Differential Expression of CD269 and CD317 Genes in Bone Marrow of Patients with Multiple Myeloma

[Expression and Significance of PD-1, PD-L1 and CTLA-4 in the Bone Marrow of Patients with Multiple Myeloma]

The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients

[Prognostic Significance of CD27 and CD56 on Newly Diagnosed MM Patients Treated with Bortezomib].

The Significance of Inflammatory Markers in the Prognosis of Newly Diagnosed Multiple Myeloma Patients

[Correlation of CD19 Positive Cell Counts in Bone Marrow with Therapeutic Efficacy in Patients with Multiple Myeloma].

Prognostic Value of Immune Status Changes after Chemotherapy in Patients with Newly Diagnosed Multiple Myeloma

[Correlation between Expression Patterns of CD117/CD200 in Plasma Cells and Molecular Genetic Prognostic Parameters in Multiple Myeloma]

Peripheral Blood Absolute Lymphocyte Count, Absolute Monocyte Count and Their Ratio in Prognosis Prediction of Newly Diagnosed Multiple Myeloma

Immunophenotype Characteristics of Patients with Multiple Myeloma in Different Risk Stratification

[Validation of the prognostic value of the Mayo MASS and R2-ISS staging systems in patients newly diagnosed with multiple myeloma: A single-center study]

Cellular immune function and its clinical implications in 45 patients with multiple myeloma